BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX), a company specializing in non-opioid pain management therapies, has announced significant changes to its leadership team amidst ongoing litigation. The company recently accepted the resignation of Anthony P. Mack as CEO and Chairman, and in his stead, has appointed Gerald Bruce as CEO and Dr. Eric Floyd as Chairman.
Gerald Bruce has a long-standing history with Virpax Pharmaceuticals. He has served as the Company’s Executive Vice President of Commercial Operations since August 2017 and has been a member of the Company’s Board since July 2021. Mr. Bruce also holds the position of President and CEO of Novvae Pharmaceuticals, Inc., a wholly-owned subsidiary of Virpax, since July 26, 2023.
Before joining Virpax, Mr. Bruce held key roles at renowned companies such as Danone Specialized Nutrition North America, Nitromed, Inc., Bristol-Meyers Squibb, and Johnson and Johnson. His extensive experience and expertise in the pharmaceutical industry are expected to steer Virpax in a positive direction. Mr. Bruce holds a BA from Lincoln University and a Master’s degree in Leadership from Georgetown University’s McDonough School of Business.
Dr. Eric Floyd, the newly appointed Chairman, brings over 25 years of pharmaceutical and biotechnology experience to his new role at Virpax. Currently serving as Senior Vice President of Regulatory Affairs and Quality Assurance at Silence Therapeutics, Dr. Floyd has had roles of increasing responsibility at leading companies like Merck, Aventis, Novartis, Lundbeck, Axovant Sciences, and Neurogene, Inc.
Dr. Floyd’s academic credentials include an undergraduate degree in Biology from the University of Illinois, a Master’s degree in Neuroscience from Tennessee State University, a Doctorate in Neurophysiology from Meharry Medical College, an Executive MBA in Pharmaceutical Marketing from Saint Josephs’ University, and a Global Executive MBA in International Business from the INSEAD Business School in France.
The outgoing CEO, Mr. Mack, expressed his confidence in the new leadership, stating, “It has been an honor to lead a team of such dedicated and talented colleagues. I am proud of what we have accomplished together and confident that Virpax under Gerald and Eric’s leadership will remain on track to begin first-in-human trials in the coming year.”
These changes reflect Virpax’s commitment to maintaining strong leadership as it navigates through complex business challenges. The company’s investors will likely be watching closely how this new leadership team will drive forward Virpax’s mission of advancing non-opioid therapies for pain management.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.